Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 3/2006

01-05-2006 | Preclinical Studies

Flutamide in unresectable pancreatic adenocarcinoma: A randomized, double-blind, placebo-controlled trial

Authors: Sanjay Singh Negi, MCh, Anil Agarwal, MCh, Adarsh Chaudhary, FRCS

Published in: Investigational New Drugs | Issue 3/2006

Login to get access
Metadata
Title
Flutamide in unresectable pancreatic adenocarcinoma: A randomized, double-blind, placebo-controlled trial
Authors
Sanjay Singh Negi, MCh
Anil Agarwal, MCh
Adarsh Chaudhary, FRCS
Publication date
01-05-2006
Publisher
Kluwer Academic Publishers
Published in
Investigational New Drugs / Issue 3/2006
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-005-3536-2

Other articles of this Issue 3/2006

Investigational New Drugs 3/2006 Go to the issue

Phase I Studies

Phase I study of Vinflunine administered as a 10-minute infusion on days 1 and 8 every 3 weeks

Phase II Studies

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma

Phase I Studies

Phase I trial of oral talactoferrin alfa in refractory solid tumors

Phase II Studies

An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma

Preclinical Studies

Interferon-α plus capecitabine and thalidomide in patients with metastatic renal cell carcinoma: A pilot study

Preclinical Studies

Cytotoxicity of sphingoid marine compound analogs in mono- and multilayered solid tumor cell cultures
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits